OBJECTIVES: Acute myeloid leukemia (AML) is a rare hematologic malignancy characterized by proliferation of myeloid blasts which is associated with poor outcomes (25.8%, 5-year survival; SEER, 2016). While AML treatment has not changed meaningfully in the past four decades, new therapies in advanced development have the potential to improve outcomes in AML. Health utilities are an important component in economic evaluation to assess the value of new treatment options. This literature review aims to identify health state utility values in adult patients with AML. METHODS: A literature search strategy for AML and health state utility values was implemented across MEDLINE, PubMed, EMBASE, PsycINFO, HTA databases, NHS Economic Evaluation Database, Cochrane Central Register of Controlled Trials, Database of Abstracts of Reviews of Effects, Cost-Effectiveness Analysis Registry, ScHARRHUD, EQ-5D database, ISPOR Scientific Presentations Database, and ISOQOL conference abstracts. 2284 records were identified. Following exclusion of records based on title and abstract, two researchers independently assessed the 52 full texts of selected articles and extracted data for eligible studies. RESULTS: Eighteen studies met the eligibility criteria. Of the studies assessed, four reported values for descriptive analyses of HRQoL, one was a review of utilities in different leukemia types, and the remaining publications used utility values in economics models. Utilities were derived from multiple methods, including proxies from other health conditions (e.g., CML, MDS; n=5), mapping (n=2), EQ-5D (n=5), physician visual analog scale ratings (n=2), reference to other publications (n=2), or was not specified (n=2). Overall, utility values for AML health states varied widely by publication: baseline AML 0.52-0.77; remission 0.74-0.99; relapse 0.3-0.8. CONCLUSIONS: Overall, this review indicates that there is a scarcity of robust utility data in AML patients. Further studies are needed to delineate better defined AML health utilities to inform the economic value of AML treatment strategies.